Published in FDA Law Weekly, April 15th, 2004
"This milestone payment represents the acknowledgement by Bristol-Myers Squibb of the progress that we have made together in the ERBITUX clinical program, which culminated in the recent approval of the drug in combination with irinotecan and as a single agent in certain patients with late-stage colorectal cancer," stated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly